SensoDetect

SensoDetect AB Confirms receipt of license payments and announces successful installation and testing of AI software in China

Källa: MFN
Positiv

Sammanfattning

SensoDetect AB bekräftar mottagna licensbetalningar från sitt joint venture i Kina. AI-mjukvaran för BERA 4.2 har installerats och testats framgångsrikt, med lovande resultat som visar snabbare och mer effektiv neurofysiologisk testning.

Analys

Bolaget har mottagit fulla licensbetalningar från sitt kinesiska joint venture, vilket är en positiv bekräftelse på samarbetet. Framgångsrik installation och lovande tidiga testresultat för AI-mjukvaran i Kina indikerar en teknologisk framsteg och potential för ökad skalbarhet och effektivitet. Nästa steg inkluderar klinisk validering och regulatoriska förberedelser för en marknadslansering i Kina.

Nyckeltal

Tid för neurofysiologisk test
< 5 min 30 sek
Tid för AI-beräkningar
< 10 sek

Insikter

  • • AI-mjukvaran visar potential att omdefiniera klinisk diagnostik genom ökad hastighet och effektivitet.
  • • Nästa steg involverar klinisk validering och NMPA-regulatoriska förberedelser för den kinesiska marknaden.
  • • Den nyligen genomförda investeringsrundan i joint venture stärker dess finansiella och teknologiska bas.

SensoDetect AB (Spotlight Stock Market: SDET) is pleased to confirm that all license payments from its joint venture, Beijing Mind Exploration Medical Technology Co., Ltd., have been received in full and on time. This marks another significant milestone in the collaboration and commercialization of SensoDetect's BERA 4.2 system and its next-generation AI-driven diagnostic platform in China.

The company further announces that the AI software has now been successfully installed and activated within the joint venture's operational framework in Beijing. The first testing series has shown very promising results, confirming that the system can now perform the entire neurophysiological test in less than 5 minutes and 30 seconds, a substantial improvement in speed and efficiency.

Even though the system processes an extremely large amount of neurophysiological data, the AI calculations can be completed in under 10 seconds - either locally on the device or through secure cloud computation. This represents a major technological leap forward, significantly improving scalability, accessibility, and reliability for both clinical and research use.

"We are very pleased to confirm that all financial commitments from our Chinese partners have been fulfilled in full and that the AI system is now live and performing beyond expectations," says Per-Anders Hedin, CEO of SensoDetect AB. "The early test results are highly encouraging and demonstrate the strength of our technology to redefine clinical diagnostics by making it faster, smarter, and more efficient than ever before."

The AI module represents the next major evolution of SensoDetect's proprietary BERA (Brainstem Evoked Response Audiometry) technology, combining advanced signal processing with modern machine learning. With the system now operational, the joint venture will move forward with extended clinical validation, NMPA regulatory preparations, and scaling for production.

This progress follows the recently completed initial investment round in the joint venture, strengthening both its financial and technological base for a large-scale launch in the Chinese market.

For more information or partnership inquiries, please contact:

PA Hedin, CEO Sensodetect AB

+46 (0)46 15 79 04pa.hedin@sensodetect.com

Fler nyheter från SensoDetect

Relaterade pressmeddelanden och bolagshändelser från samma bolag.

Se bolagssidan
SensoDetect: SensoDetect AB Confirms receipt of license payments and announces successful installation and testing of AI software in China - pressmeddelande och analys | Tickr